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Further Discussion on the Treatment of Hypertension
1. Hermida RC, Ayala DE, Mojón A, et al. Influence of circadian time of
hypertension treatment on cardiovascular risk: results of the MAPEC
study. Chronobiol Int. 2010;27:1629–1651.
Background:
A patient’s blood pressure changes throughout the day, in sync with the rest-activity cycle. The
body’s circadian rhythm contributes to fluctuation in blood pressure and affects the body’s
response to antihypertensive medications. Traditionally, blood pressure medications are
prescribed to be taken in the morning. Patients on more than 1 blood pressure medication
usually take their medications all at once. Recent studies have shown that sleep time blood
pressure may be a more important factor than daytime blood pressure readings in fatal and
nonfatal cardiovascular disease events.
Study type:
Randomized controlled trial, results evaluated from Ambulatory Blood Pressure Monitoring for
Prediction of Cardiovascular Events Study (MAPEC)
2201 subjects diagnosed with untreated or resistant hypertension (awake BP mean greater than
or equal to 135/85, asleep BP mean greater than or equal to 120/70), 1109 patients allocated to
treatment in the morning, 1092 allocated to take >=1 medication at bedtime. Blood pressure was
measured for 48 hours annually for a mean follow up of 5.6 years
Results:
-Differences between groups for mean BP while awake were not significant p=0.546
-Proportion of patients with non dipper blood pressure was lower in bedtime group than morning
group 34% versus 62% p<0.001
-Relative risk of major CVD events (death, MI, ischemic stroke, hemorrhagic stroke) 0.39
p<0.001 when greater than or equal to one medication at bedtime was taken versus all
medications ingested in the morning
Conclusions:
-Patients experienced better blood pressure control during sleep while taking at least one or
more blood pressure medications at bedtime
-Major CVD events were lower in patients who took one or more of their blood pressure
medications at bedtime NNT 30 over 5.6 years
-In comparison- patients with moderate to severe hypertension (SBP > 160), NNT for a patient
taking low dose thiazide diuretics for 5 years was 20 in the primary prevention of cardiovascular
events 1
2. Webb AJ, Fischer U, Mehta Z, Rothwell PM. Effects of antihypertensive-drug
class on interindividual variation in blood pressure and risk of stroke: a
systematic review and meta-analysis. Lancet. 2010 Mar 13;375(9718):906-15.
Background:
Studies show an increase in 20 mm Hg of SBP doubles the risk of stroke in individuals from 40-69
years of age. All hypertensive drugs have been shown to decrease stroke and cardiovascular
events with decreasing mean blood pressure. However, class variations may exist. Previous
studies showed CCB decreased stroke risk more than what is expected from simply decreasing
blood pressure, hence there may be more to benefit from certain antihypertensive agents than
just the lowering of mean blood pressure.
Study type:
Meta-analysis and systematic review
Study evaluated 398 RCT which studied changes in interindividual variance in blood pressure at
the highest dose of different antihypertensive drugs with mean SBP measured at one year in

each study. Eight drug classes were evaluated: dihydropyridine CCB, non-dihydropyridine CCB,
thiazide and thiazide like diuretics, ACEi, beta blockers, ARB, alpha1 blockers
Results:
-Interindividual variation in SBP was decreased by CCB (VR 0.81, p<0.0001), non-loop diuretics
(0.97, p= 0.007), but increased by ACEi (1.08, p=0.008), ARB (1.16, p=0.0002), beta blockers
(1.17, p=0.0007) (each drug class was compared to all other drug classes)
-A significant reduction in stroke with lower SD for systolic blood pressure was shown p=0.012
Conclusions:
-CCB and thiazide diuretics decrease interindividual variation of blood pressure
-Blood pressure medications which decreased interindividual variation showed statistically
significant reduction in stroke risk
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